Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines. Issue 2 (21st January 2022)

• Record Type: Journal Article
• Authors: Maltezou, Helena C.; Anastassopoulou, Cleo; Hatziantoniou, Sophia; Poland, Gregory A.; Tsakris, Athanasios
• Is Part Of: Vaccine. Volume 40:Issue 2(2022)
• Page Start: 183
• Page End: 186
• Publication Date: 2022-01-21
• Subjects: COVID-19 -- Vaccine -- Allergy -- Anaphylaxis -- Hypersensitivity -- VAERS -- EudraVigilance; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2021.11.066
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: We retrieved data on 8940 anaphylaxis cases post-COVID-19 vaccination from the US Vaccine Adverse Event Reporting System and the European EudraVigilance from week 52/2020 through week 31/2021 and compared them with those of other vaccines. Overall, 837, 830, 000 COVID-19 vaccine doses were delivered in the US and Europe during the study period, for which the vaccine name was known. The mean anaphylaxis rate was estimated at 10.67 cases per 10 6 doses of COVID-19 vaccines (range: 7.99-19.39 cases per 10 6 doses depending on the vaccine). COVID-19 vaccines ranked fifth in reported anaphylaxis rates, behind rabies, tick-borne encephalitis, measles-mumps-rubella-varicella, and human papillomavirus vaccines (70.77, 20, 19.8, and 13.65 cases per 10 6 vaccine doses, respectively). COVID-19 vaccines are within the range of anaphylaxis rates reported across several common vaccines in these two passive reporting systems. These data should be communicated to reassure the general population about the safety profile of COVID-19 vaccines.